Health Blueprint

Back to Longevity News

News summary

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

Source: GlobeNewswire - Biotech Financing • Published: 21 Oct 2026, 00:52

Summarized by Masters of Longevity from GlobeNewswire - Biotech Financing.

Announcement that a clinical-stage hematology biotech priced an upsized $450 million common stock offering to fund development and commercialization plans.

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
Key Takeaways
  • Disc Medicine is selling 6,000,000 shares at $75.00 per share.
  • Underwriters have a 30-day option to buy up to 900,000 additional shares.
Read the full article at GlobeNewswire - Biotech Financing ↗

Continue exploring

Recommended MoL Picks

MoL PickMOTS-c: Where the Evidence EndsStudies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.MoL PickNucleotides and Longevity: Is the Evidence Ready?They help build DNA and keep cells working. Early human studies make nucleotide supplements interesting—but leave important questions about healthy ageing unanswered. Yet.